Maxim Group began coverage on shares of Can Fite Biopharma Ltd (AMEX:CANF) in a research note issued on Friday, StockTargetPrices.com reports. The brokerage set a “buy” rating and a $7.00 price target on the stock.
Can Fite Biopharma (AMEX CANF) opened at 1.53 on Friday. Can Fite Biopharma has a one year low of $1.50 and a one year high of $2.82. The company’s 50-day moving average price is $1.77 and its 200-day moving average price is $1.85. The stock’s market capitalization is $23.72 million.
About Can Fite Biopharma
Can Fite Biofarma Ltd is an Israel-based biopharmaceutical company. The Company develops new treatments for autoimmune diseases and cancer. The Company’s drugs are CF101 for Psoriasis treatment, RA treatment, for the treatment of Keratoconjunctictivitis Sicca, for the treatment of Glaucoma, among others; and CF102 for the treatment of liver diseases.
Receive News & Ratings for Can Fite Biopharma Ltd Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Can Fite Biopharma Ltd and related companies with MarketBeat.com's FREE daily email newsletter.